Evidence map›Paper›PMID 40161803›Full record

ArticlebioRxiv : the preprint server for biology2025

Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence.

Hadeesha Piyadasa, Benjamin Oberlton, Mikaela Ribi, Jolene S Ranek, Inna Averbukh, Ke Leow, Meelad Amouzgar, Candace C Liu, Noah F Greenwald, Erin F McCaffrey and 29 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors.

Hadeesha PiyadasaDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-0276-6590
Benjamin OberltonDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Mikaela RibiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Jolene S RanekDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Inna AverbukhDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Ke LeowDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Meelad AmouzgarDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Candace C LiuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Noah F GreenwaldDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Erin F McCaffreyDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Rashmi KumarDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Selena FerrianDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Albert G TsaiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Ferda FilizDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Christine Camacho FullawayDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Marc BosseDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Sricharan Reddy VarraDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Alex KongDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Cameron SowersDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Melanie Hayden GephartDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Pablo Nuñez-PerezDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
EnJun YangParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Mike TraversParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Michael J SchachterParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Samantha LiangParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Maria R SantiChildren's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, PA, USA.
Samantha BucktroutParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Pier Federico GherardiniParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
John ConnollyParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Kristina ColeChildren's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, PA, USA.
Michael E BarishParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Christine E BrownDepartments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Derek A OldridgeParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Richard R DrakeDepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Joanna J PhillipsDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Hideho OkadaParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Robert PrinsParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Sean C BendallDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Michael AngeloDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-1531-5067

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1M
Uncoupling Age- Versus Cognitive-Related Cellular Senescence in Alzheimer's DiseaseR01AG068279 · NIA · STANFORD UNIVERSITY · PI BENDALL, SEAN CURTIS · 2020 to 2024
$1.9M
Regulating the glioma immune microenvironmentR01NS131474 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanna Phillips · 2024 to 2026
$1.8M
The Penn-StARR Program for Research in ResidencyR38HL143613 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KLEIN, PETER S · 2018 to 2021
$1.4M
Simplified Glycan Profiling Workflows of Captured Immune Glycoproteins and CellsU01CA242096 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M, DRAKE, RICHARD R. · 2019 to 2021
$818k
USING DEEP MUTATIONAL SCANNING TO CHARACTERIZE TUMOR-IMMUNE INTERACTIONSK00CA264307 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NOAH GREENWALD · 2025 to 2026
$192k
Comprehensive profiling of the tumor microenvironment to predict patient response to immunotherapyF99CA264307 · NCI · STANFORD UNIVERSITY · PI GREENWALD, NOAH · 2021 to 2022
$79k
Predicting response to anti-PD-1 therapy in triple negative breast cancer by comprehensive profiling of the tumor microenvironmentF31CA246880 · NCI · STANFORD UNIVERSITY · PI GREENWALD, NOAH · 2020 to 2021
$53k
NCI NIH HHS F31 CA246880NCI NIH HHS F99 CA264307NCI NIH HHS K00 CA264307NCI NIH HHS P50 CA097257NCI NIH HHS T32 CA009140NCI NIH HHS U01 CA242096NHLBI NIH HHS R38 HL143613NIA NIH HHS R01 AG068279NINDS NIH HHS R01 NS131474
6 · The paper itself

Abstract

Gliomas are among the most lethal cancers, with limited treatment options. To uncover hallmarks of therapeutic escape and tumor microenvironment (TME) evolution, we applied spatial proteomics, transcriptomics, and glycomics to 670 lesions from 310 adult and pediatric patients. Single-cell analysis shows high B7H3+ tumor cell prevalence in glioblastoma (GBM) and pleomorphic xanthoastrocytoma (PXA), while most gliomas, including pediatric cases, express targetable tumor antigens in less than 50% of tumor cells, potentially explaining trial failures. Longitudinal samples of isocitrate dehydrogenase (IDH)-mutant gliomas reveal recurrence driven by tumor-immune spatial reorganization, shifting from T-cell and vasculature-associated myeloid cell-enriched niches to microglia and CD206+ macrophage-dominated tumors. Multi-omic integration identified N-glycosylation as the best classifier of grade, while the immune transcriptome best predicted GBM survival. Provided as a community resource, this study opens new avenues for glioma targeting, classification, outcome prediction, and a baseline of TME composition across all stages.

Identifiers

PMID40161803
PMCPMC11952471

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.